NCT00003967View on ClinicalTrials.gov

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

April 30, 2006

Conditions

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

Interventions

DRUG

etoposide

DRUG

topotecan hydrochloride

Trial Locations (6)

21202

Mercy Medical Center, Inc., Baltimore

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

52242-1009

Holden Comprehensive Cancer Center at The University of Iowa, Iowa City

08103

Cooper Hospital/University Medical Center, Camden

44106-5065

Ireland Cancer Center, Cleveland

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00003967 - Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter